Xiaoxing Feng

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers

Emma Beddowes, James Spicer, Pui Ying Chan et al. · Journal of Clinical Oncology · 2017 · 122 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma

Maeve A. Lowery, Kenneth H. Yu, David P. Kelsen et al. · Cancer · 2017 · 86 citations

Medicine, Oncology, Pharmacology +17

A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma

Peter E. Hall, Rachel Lewis, Nelofer Syed et al. · Clinical Cancer Research · 2019 · 69 citations · Full text

Medicine, Oncology, Pharmacology +13

Inhibition of the transient receptor potential melastatin-2 channel causes increased DNA damage and decreased proliferation in breast adenocarcinoma cells

Mandi M. Hopkins, Xiaoxing Feng, Mengwei Liu et al. · International Journal of Oncology · 2015 · 60 citations · Full text

Life Sciences, Cell Biology, Oncology +14

Enhanced cytotoxicity in triple-negative and estrogen receptor-positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel

David W. Koh, Daniel P. Powell, Steven D. Blake et al. · Oncology Reports · 2015 · 50 citations · Full text

Medicine, Oncology, Pharmacology +10